Delving into the Latest Updates on CREPT-618 with Synapse

Overview

Basic Info

Drug Type

Nucleic acid drugs

Synonyms

CREPT-618

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Advanced Malignant Solid NeoplasmMetastatic Solid TumorLocally Advanced Hepatocellular Carcinoma

Inactive Indication

Primary Biliary Cholangitis

Originator Organization

Heya (Beijing) Pharmaceutical Technology Co., Ltd

Active Organization

Cancer Hospital Chinese Academy of Medical Sciences

Inactive Organization

Heya (Beijing) Pharmaceutical Technology Co., Ltd

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The goal of this Phase I/II observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors. The study utilizes multi-dimensional precision screening (including WES, RNAseq, mIHC, and quantitative proteomics) to match patients with specific sub-protocols.
Key questions it aims to answer:
Assess the safety of innovative therapies in rare tumor populations. Evaluate the objective response rate (ORR) and other efficacy metrics. Explore biomarkers related to therapeutic efficacy. Participants: Patients with metastatic or advanced rare solid tumors who have failed standard therapy or have no standard treatment options.

Start Date01 Jan 2026

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

ChiCTR2600119918

/ Not yet recruitingNot ApplicableIIT

A Study on the Safety, Tolerability, and Preliminary Efficacy of CREPT-618 in Patients with Metabolic Dysfunction-Associated Steatohepatitis

Start Date31 Dec 2025

Sponsor / Collaborator

Tianjin Fifth Central Hospital

100 Clinical Results associated with CREPT-618

Login to view more data

100 Translational Medicine associated with CREPT-618

Login to view more data

100 Patents (Medical) associated with CREPT-618

Login to view more data

100 Deals associated with CREPT-618

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	-	Cancer Hospital Chinese Academy of Medical Sciences	01 Jan 2026
Metastatic Solid Tumor	Phase 2	-	Cancer Hospital Chinese Academy of Medical Sciences	01 Jan 2026
Locally Advanced Hepatocellular Carcinoma	Phase 1	China	Cancer Hospital Chinese Academy of Medical Sciences	15 Sep 2025
Primary Biliary Cholangitis	Clinical	China	Heya (Beijing) Pharmaceutical Technology Co., Ltd	30 Sep 2025